CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Non-Anchoring Strategy ControlWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug947 Fixed Anchoring Strategy Wiki 1.00
drug1801 Personalized Anchoring Strategy Wiki 1.00
drug512 Camostat Mesilate Wiki 0.45
drug1853 Placebo oral tablet Wiki 0.19

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Mindfulness Takes Practice: mHealth Tools for Building Persistent Mindfulness Meditation Habits

The purpose of the study is to optimize the delivery of mHealth tools to support the formation of persistent mindfulness meditation routines. Aim 1: Identify the efficacy of the anchoring strategy on the persistence of daily meditation practice. H1: Persistence (measured through repeated observations of panel regression models of the daily likelihood of mindfulness mediation over the 16-week follow-up period) will be greater among AG as compared to CG. Aim 2: Determine participant phenotypes that are (a) associated with successfully anchoring daily meditation or (b) likely to need additional supports. Potential moderators of the anchoring strategy's success include participants' daily schedule, type of work, household composition, motivation, time and risk preferences, and prior exposure to mindfulness, which will be analyzed in the panel regression model framework above. Aim 3: Determine the optimal type, timing, and sequence of push notifications for encouraging daily mindfulness meditation within and across study groups. The efficacy of each push notification type (tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders), timing, and dynamics on the anchoring of daily meditation will inform a subsequent, just-in-time adaptive intervention (JITAI). Impact: This study will inform an optimal JITAI R01 proposal that will personalize the type and temporal dynamics of app-based daily supports for successfully routinizing daily meditation, and determine its effects on mental health, specifically PTSD. Lifetime prevalence of PTSD is 7% in adults and meditation is known to reduce PTSD. If effective

NCT04378530 Stress Habits Behavioral: Personalized Anchoring Strategy Behavioral: Non-Anchoring Strategy Control Behavioral: Fixed Anchoring Strategy

Primary Outcomes

Description: Acceptability will be measured using a satisfaction survey at the end of the study, following all other measures (satisfied with the intervention and perceive daily meditation and app components as appropriate and useful)

Measure: Feasibility: Acceptability

Time: Measured at post-intervention about experience in study (8 weeks) and follow up (16 weeks)

Description: Demand will be measured using objective app usage data provided by the Calm app informatics. Data will be on individual app feature(s) used, time of day the app/feature was used, and time spent in meditation.

Measure: Feasibility 2: Demand

Time: Measured at post-intervention about experience in study (8 weeks) and follow up (16 weeks)

Secondary Outcomes

Description: Stress will be measured using the Perceived Stress Scale -10 item, with scores ranging from 10-40) and a higher score indicates a worse outcome.

Measure: Stress

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: Anxiety will be measured using the Hospital Anxiety and Depression Scale, with scores ranging from 0-21, and a higher score indicates a worse outcome.

Measure: Anxiety

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: Depression will be measured using the Hospital Anxiety and Depression Scale, with scores ranging from 0-21, and a higher score indicates a worse outcome.

Measure: Depression

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: Global health will be measured using the PROMIS Global Health Scale v1.2, with scores ranging from 4-20, and higher scores indicate a better outcome.

Measure: Global Health

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: PTSD will be measured using the Impact of Events Scale-Revised, with scores ranging from 0-88, with higher scores indicating a worse outcome.

Measure: PTSD

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: Emotional regulation will be measured using the Difficulties in Emotional Regulation -18, with scores ranging from 18-90, with higher scores indicating a worse outcome.

Measure: Emotional Regulation

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: Habit will be measured using the habit questionnaire scored is the sum across the four questions (which are individually scored from 1-5 based on degree of agreement), where a higher score indicates more behavioral automaticity (strong habit).

Measure: HABIT

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)

Description: COVID-19 as a mediator to the other health and well-being measures will be measured through a COVID-19 questionnaire created by the researcher.

Measure: COVID-19

Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)


No related HPO nodes (Using clinical trials)